文献速递MDS 与骨髓增殖性肿瘤

MDM2拮抗剂idasanutlin治疗真性红细胞增多症患者:一项单臂2期研究结果

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
PubMed 文献 · Blood Adv · 2022-01-01

这项开放标签2期研究评估idasanutlin在羟基脲耐药或不耐受的真性红细胞增多症患者中的疗效,给药方案为每28天周期第1至5天每日一次。27例患者中16例可评估,9例(56%)达到血细胞比容控制,8例(50%)达到完全血液学缓解,但恶心(93%)等胃肠道毒性导致长期耐受性差。

要点

  • idasanutlin在羟基脲耐药或不耐受的真性红细胞增多症患者中显示临床活性,可快速降低JAK2 V617F等位基因负荷。
  • 可评估患者中血细胞比容控制率56%,完全血液学缓解率50%。
  • 恶心(93%)、腹泻(78%)、呕吐(41%)为最常见不良事件,长期耐受性差。

核心结论

  • idasanutlin给药方案在羟基脲耐药或不耐受的真性红细胞增多症患者中显示临床活性并能快速降低JAK2等位基因负荷,但与低级别胃肠道毒性相关,导致长期耐受性差。

研究设计与样本

  • 开放标签2期研究,纳入羟基脲耐药或不耐受(符合欧洲白血病网标准)且依赖放血治疗的真性红细胞增多症患者,允许既往接受芦可替尼治疗。
  • idasanutlin每日一次,每28天周期第1至5天给药。
  • 所有患者(n=27)均接受idasanutlin治疗,16例在32周时有缓解评估。
  • 主要终点为32周时脾肿大患者的复合缓解(血细胞比容控制且脾体积缩小>35%)和无脾肿大患者的血细胞比容控制。

主要发现

  • 基线有脾肿大的可评估患者(n=13)中,9例(69%)达到任何程度的脾体积缩小,1例达到复合缓解。
  • 9例患者(56%)达到血细胞比容控制,8例患者(50%)达到完全血液学缓解。
  • 可评估患者中43%(6/14)在32周时骨髓增殖性肿瘤症状评估表总症状评分降低≥50%。
  • 恶心(93%)、腹泻(78%)、呕吐(41%)为最常见不良事件,3级及以上恶心3例(11%)、呕吐1例(4%)。
  • JAK2 V617F等位基因负荷早期(3个周期后)即降低,中位降低76%,且与达到完全血液学缓解和血细胞比容控制相关。

关键数值与推荐

  • 主要终点复合缓解:脾肿大患者需同时达到血细胞比容控制和脾体积缩小>35%,无脾肿大患者仅需血细胞比容控制,评估时间为32周。
  • 完全血液学缓解和血细胞比容控制为关键次要终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idasanutlin, an MDM2 antagonist, showed clinical activity and a rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open-label phase 2 study evaluated idasanutlin in patients with hydroxyurea (HU)-resistant/-intolerant PV, per the European LeukemiaNet criteria, and phlebotomy dependence; prior ruxolitinib exposure was permitted. Idasanutlin was administered once daily on days 1 through 5 of each 28-day cycle. The primary end point was composite response (hematocrit control and spleen volume reduction > 35%) in patients with splenomegaly and hematocrit control in patients without splenomegaly at week 32. Key secondary end points included safety, complete hematologic response (CHR), patient-reported outcomes, and molecular responses. All patients (n = 27) received idasanutlin; 16 had response assessment (week 32). Among responders with baseline splenomegaly (n = 13), 9 (69%) attained any spleen volume reduction, and 1 achieved composite response. Nine patients (56%) achieved hematocrit control, and 8 patients (50%) achieved CHR. Overall, 43% of evaluable patients (6/14) showed a ≥50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (week 32). Nausea (93%), diarrhea (78%), and vomiting (41%) were the most common adverse events, with grade ≥ 3 nausea or vomiting experienced by 3 patients (11%) and 1 patient (4%), respectively. Reduced JAK2 V617F allele burden occurred early (after 3 cycles), with a median reduction of 76%, and was associated with achieving CHR and hematocrit control. Overall, the idasanutlin dosing regimen showed clinical activity and rapidly reduced JAK2 allele burden in patients with HU-resistant/- intolerant PV but was associated with low-grade gastrointestinal toxicity, leading to poor long-term tolerability. This trial was registered at www.clinincaltrials.gov as #NCT03287245.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mascarenhas J, Passamonti F, Burbury K, et al. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Adv. 2022. PMID: 34933330. doi:10.1182/bloodadvances.2021006043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。